Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Non Operating Income: 2016-2025

Historic Non Operating Income for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to -$10,000.

  • Akebia Therapeutics' Non Operating Income rose 41.18% to -$10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $230,000, marking a year-over-year decrease of 67.00%. This contributed to the annual value of $94,000 for FY2024, which is 89.40% down from last year.
  • Akebia Therapeutics' Non Operating Income amounted to -$10,000 in Q3 2025, which was up 64.29% from -$28,000 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Non Operating Income peaked at $1.3 million during Q2 2021, and registered a low of -$43,000 during Q3 2023.
  • Its 3-year average for Non Operating Income is $105,091, with a median of -$10,000 in 2025.
  • In the last 5 years, Akebia Therapeutics' Non Operating Income surged by 604.35% in 2022 and then crashed by 290.00% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Non Operating Income (Quarterly) stood at $560,000 in 2021, then dropped by 22.50% to $434,000 in 2022, then spiked by 51.61% to $658,000 in 2023, then plummeted by 91.64% to $55,000 in 2024, then spiked by 41.18% to -$10,000 in 2025.
  • Its last three reported values are -$10,000 in Q3 2025, -$28,000 for Q2 2025, and $213,000 during Q1 2025.